P

Parabilis Medicines

HealthUnited States

Parabilis Medicines is a biotechnology startup focused on developing therapies for 'undruggable' targets, particularly in cancer treatment. The company has raised significant funding to advance its innovative peptide drugs, known as 'Helicons', which aim to target difficult-to-reach cancer-driving proteins. Their most advanced candidate, zolucatetide, is set to enter Phase 3 trials for desmoid tumors in 2027.

$670M · IPOVisit website ↗

🏆 Featured in Datapile’s Q2 2026 USA Funding Report

Read the Q2 2026 USA report →
Add this badge to your site
Featured in Datapile’s Q2 2026 USA Funding Report
<a href="https://datapile.co/reports/q2-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q2 2026 USA Funding Report</a>

Funding history

  1. $670MIPO2026-06-10
    Source: news.google.com ↗

Founder

G
Gregory Verdine
CEO

Investors in Parabilis Medicines

Backers from this company's tracked funding rounds.

  • Regeneron Pharmaceuticals

More Health companies

Recently funded startups in the same category.

Related on Datapile